Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study

被引：1
|
作者：
Croop, Robert [1 ]
Ailani, Jessica [2 ]
Kudrow, David
Smith, Timothy [3 ]
Lipton, Richard [4 ]
Thiry, Alexandra [1 ]
Jensen, Christopher [1 ]
Kamen, Lisa [1 ]
机构：
[1] Biohaven Pharmaceut, New Haven, CT USA
[2] Medstar Georgetown Neurol, Washington, DC USA
[3] Study Metrix Res, St Petersburg, FL USA
[4] Albert Einstein Coll Med, New York, NY USA
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000202051
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P10-12.010
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study
    Ailani, Jessica
    Kudrow, David
    Smith, Timothy
    Lipton, Richard B.
    Goadsby, Peter J.
    Thiry, Alexandra
    Jensen, Christopher M.
    Kamen, Lisa
    Coric, Vladimir
    Croop, Robert
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 132 - 134
  • [2] Effects of rimegepant 75 mg on monthly migraine days: A 52-week, open-label extension study
    Ailani, J.
    Kudrow, D.
    Smith, T. R.
    Lipton, R. B.
    Thiry, A. C.
    Jensen, C. M.
    Kamen, L.
    Coric, V
    Croop, R.
    HEADACHE, 2022, 62 : 139 - 140
  • [3] Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52Week, Open-Label Extension Study
    Ailani, J.
    Kudrow, D.
    Smith, T.
    Lipton, R.
    Thiry, A. C.
    Jensen, C. M.
    Kamen, L.
    Coric, V.
    Croop, R.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [4] Effect of long-term preventive treatment with oral rimegepant 75 mg on migraine-related disability: A 52-week, open-label extension study
    Lipton, R. B.
    McAllister, P.
    Turner, I. M.
    Schim, J. D.
    Litalien, G. J.
    Jensen, C. M.
    Thiry, A. C.
    Kamen, L.
    Coric, V
    Croop, R.
    HEADACHE, 2022, 62 : 136 - 137
  • [5] Aripiprazole versus olanzapine in a 52-week, open-label extension study
    McQuade, R
    Kostic, D
    Marcus, R
    Carson, W
    Torbeyns, A
    Kerselaers, W
    Yocca, F
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 496 - 497
  • [6] Patterns of medication utilization and migraine frequency in adults using rimegepant for both preventive and acute treatment for migraine: Results from a 52-week, open-label extension study
    Hutchinson, S.
    Goodrich, R.
    HEADACHE, 2022, 62 (07): : 926 - 927
  • [7] Patterns of Medication Utilization and Migraine Frequency in Adults Using Rimegepant for Both Preventive and Acute Treatment for Migraine: Results From a 52-Week, Open-Label Extension Study
    Hutchinson, Susan
    Mullin, Kathleen
    Pavlovic, Jelena
    Lipton, Richard
    Jensen, Christopher
    Thiry, Alexandra
    Kamen, Lisa
    Croop, Robert
    NEUROLOGY, 2023, 100 (17)
  • [8] Aripiprazole versus olanzapine in schizophrenia: A 52-week, open-label extension study
    McQuade, R
    Kostic, D
    Marcus, R
    Carson, W
    Iwamoto, T
    Torbeyns, A
    Kerselaers, W
    Yocca, F
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S173 - S174
  • [9] Rimegepant 75 mg Results in Reductions in Monthly Migraine Days: Secondary Analysis of a Multicenter, Open Label Long-term Safety Study of Rimegepant for the Acute Treatment of Migraine
    McGinley, James S.
    L'Italien, Gilbert J.
    Thiry, Alexandra
    Croop, Robert
    Coric, Vladimir
    Lipton, Richard B.
    NEUROLOGY, 2020, 94 (15)
  • [10] Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study
    Lipton, Richard B.
    Kudrow, David
    Smith, Timothy
    Ailani, Jessica
    Goadsby, Peter J.
    Kamen, Lisa
    Thiry, Alexandra
    Jensen, Christopher M.
    Coric, Vladimir
    Croop, Robert
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 131 - 132
12345